Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
NCT ID: NCT06445127
Last Updated: 2025-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
15 participants
OBSERVATIONAL
2024-05-07
2025-04-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Functional MRI in Lupus Nephritis
NCT01731054
Dynamic Imaging of Variation in Lupus Nephritis
NCT03180021
Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis
NCT05845151
Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients
NCT06287125
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
NCT01470183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Known Lupus Nephritis, with elevated UPCR result
Patients will have one scan at baseline, and one every 4 weeks thereafter for 3 visits. The final imaging session is after 6 months of routine therapy.
No interventions assigned to this group
No known lupus nephritis
Patients will have one MRI
No interventions assigned to this group
Known Lupus Nephritis, with normal Urine Protein Creatinine Ratio (UPCR) result
Patients will have one scan at baseline, and one every 4 weeks thereafter for 3 visits.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any patient that is receiving renal dialysis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Scientific Affairs, LLC
INDUSTRY
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Homa Timlin, MD, MSc, MRCP, CCST
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00354110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.